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Neuromyelitis optica (NMO) is a recurrent inﬂammatory disease that preferentially targets the optic nerves and spinal cord
leading to blindness and paralysis. The hallmarks of NMO include bilateral optic neuritis and longitudinally extensive transverse
myelitis. Woman and African Americans are overrepresented in the US patient population. NMO is associated with the NMO-IgG
biomarker, which targets the aquaporin-4 water channel on astrocytes. The humoral pathology of NMO lesions include IgG and
IgM deposits and inﬁltration by granulocytes suggesting that the NMO-IgG may be involved in the pathogenesis of disease. This
review of the recent NMO literature covers the clinical features, epidemiology, radiology and pathology of disease and includes
discussion of the important basic science research work in the ﬁeld.
1.Introduction
Neuromyelitis optica (NMO) is an autoimmune inﬂamma-
tory disorder of the central nervous system that predomi-
nately aﬀects the optic nerves and spinal cord.
In 1870, Allbutt was the ﬁrst to report a case of NMO
[1], but it was Devic who described the disorder in detail,
and summarized 16 cases in the existing literature in 1894
[2]. Based on this initial description, historically, NMO has
been regarded as a severe, generally monophasic disorder
of the optic nerves and spinal cord and was thought to
be a variant of multiple sclerosis (MS). A convincing body
of evidence in the past decade has established NMO as a
distinct disease entity from MS. NMO is now recognized
as a recurrent disease that largely targets the spinal cord
and optic nerves but can also aﬀect the brain as well. NMO
occupies a unique position in the spectrum of inﬂammatory
central nervous system demyelinating disorders in that it is
the only such disorder that has an associated disease-speciﬁc
antibody, aquaporin-4 antibody (AQP4 Ab), or NMO-
IgG. Recognition of this antibody has been instrumental
in elucidating the underlying pathobiology and in guiding
treatment options for NMO.
2.ClinicalFeatures
The clinical hallmarks of NMO are acute optic neuritis
that is often bilateral and transverse myelitis that is often
longitudinally extensive. Commonly reported symptoms
include unilateral and bilateral loss of visual acuity, ocular
pain, severe paraplegia, a symmetric sensory level, bladder
dysfunction, paroxysmal tonic spasms of the trunk and
limbs, and Lhermitte’s phenomenon [3, 4]. Rostral extension
of cervical cord lesions into the cervicomedullary junction
can cause symptoms such as acute respiratory decompen-
sation, nausea, intractable vomiting, and hiccups. These
symptoms can precede or occur in association with the more
typical features of optic neuritis or transverse myelitis [3, 5–
7].
Clinical features attributable to locations outside of the
optic nerves and spinal cord can also occur in patients
with NMO. Hypothalamic-pituitary axis dysfunction can
manifest as hypersomnolence, hyponatremia, hypothermia,
hypothyroidism, and hyperprolactinemia [8]. In addition,
confusion, abrupt changes in level of consciousness, cortical
blindness, and imaging ﬁndings suggestive of posterior
reversible encephalopathy syndrome (PRES) have also been
reported [9].2 Neurology Research International
The clinical course of NMO historically took one of
two forms: monophasic or relapsing, with relapsing forms
comprising approximately 80–90% of cases. However, after
an index event, the distinction between monophasic and
relapsing NMO is often diﬃcult to make since relapses can
occur many years after an event. In the vast majority of cases
(∼80%), a relapse occurs by 2-3 years after the index event
[3, 10]. Clinical features that may predict a relapsing course
of disease include older age, female gender, less severe motor
impairment with the initial myelitis event, and evidence of
systemic autoimmunity [3].
Clinical attacks typically progress over days, with varying
degrees of recovery seen in the ensuing weeks to months.
Recovery is usually incomplete, and most patients sustain
residual disability, which increases with subsequent attacks
[3]. Factors predictive of mortality in patients with relapsing
NMO include the presence of other systemic autoimmune
disorders, higher attack frequency in the ﬁrst two years, and
poor motor recovery following the index myelitis event [10,
11]. Longitudinal case series of NMO patents with follow-
up ranging from 5 to 10 years have demonstrated that the
majority of patients (47–100%) have signiﬁcant ambulatory
diﬃculties at follow-up. Residual visual deﬁcits are also
common, with >60% of patients reporting signiﬁcant vision
loss in at least one eye. Mortality due to respiratory failure
has been reported to take place in up to 32% of patients
[12, 13]. Of note, this mortality ﬁgure was derived from
the original Mayo Clinic study [3], which took place prior
to the widespread recognition of NMO and NMOSDs, and
the patient population may have been biased with respect
to clinical disease severity. Therefore, the prognosis of NMO
may not be as grave as was reported in these earlier studies.
In 1999, Wingerchuk et al. proposed diagnostic criteria
for NMO which were based on clinical and radiographic
features [3]. With the discovery of AQP4-Ab, these criteria
were revised in 2006 to include the testing of this disease-
speciﬁc antibody. In addition, the necessary clinical features
included were modiﬁed and simpliﬁed in an attempt to
improve the diagnostic properties of the criteria. At present,
the 2006 proposed diagnostic criteria for NMO consist of the
presence of optic neuritis and transverse myelitis as well as 2
out of 3 of a contiguous spinal cord MRI lesion extending
over more than 3 vertebral segments (i.e., longitudinally
extensive),brainMRInotmeetingdiagnosticcriteriaforMS,
and NMO-IgG seropositive status [14]. These criteria are
99% sensitive and 90% speciﬁc for the diagnosis of NMO
and have been independently validated in diﬀerent patient
populations [15].
Therecentliteraturesuggeststhatinadditiontoitsutility
in the diagnosis of NMO, the presence of NMO-IgG may
have a role in disease prognosis. In a prospective study
of patients with longitudinally extensive transverse myelitis
(LETM), 55% of those positive for NMO-IgG relapsed
with recurrent LETM or optic neuritis, while none of the
seronegative patients relapsed [4]. Similarly, in a series of
patients with recurrent optic neuritis, the presence of NMO-
IgG heralded a 50% chance of developing transverse myelitis
[16], while only 6.6% of seronegative patients developed
transverse myelitis. More recently, Jarius et al. found that in
acute monosymptomatic optic neuritis, 50% of NMO-IgG
seropositive patients progressed to NMO within 12 months,
while none of the seronegative patients progressed after a
median follow-up of 26 months [17].
In light of the fact that NMO is a disorder that has
the potential to cause signiﬁcant disability, the ability to
recognize and diﬀerentiate NMO and related disorders from
other demyelinating disorders is important from a clinical
perspective. The term “NMO spectrum disorders” has been
coined to reﬂect a variety of disorders thought to be related
to NMO but do not quite meet the clinical diagnostic criteria
for deﬁnite NMO. Disorders that are typically included in
thisclassiﬁcationareNMO-IgGseropositivelimitedformsof
NMO (single or recurrent LETM, recurrent or simultaneous
bilateral ON), Asian opticospinal MS (OSMS), optic neuritis
or LETM associated with systemic autoimmune disease,
and optic neuritis or myelitis associated with brain lesions
typical of NMO (e.g., hypothalamic or brainstem lesions)
[12]. Whether the NMO-IgG seronegative forms of these
disorders are a forme fruste of classic NMO or whether they
are variants of other autoimmune diseases is, at present,
unclear. Until we are able to better identify with certainty
that these are distinct disorders, the designation of NMO
spectrum disorders is useful, as it has speciﬁc prognostic
and therapeutic implications for these potentially related
disorders.
3. Epidemiology
NMO has a distinct epidemiological proﬁle in comparison
to MS. The median age of onset of NMO is typically in the
fourth or ﬁfth decade, which is older than the average age of
onset of MS. The age of onset can be quite variable, however,
and NMO is occasionally seen in children and the elderly.
There is a signiﬁcant female predominance in both diseases,
but it is even more polarized in NMO, with a female-to-male
ratio ranging from 5–11:1 [3, 10, 13, 18].
From a global perspective, NMO occurs much more
commonly in nations with a predominately nonwhite pop-
ulation make-up, where it is a common cause of CNS
demyelination. In Japan, up to 15–40% of MS is comprised
of the opticospinal variant, which may be a synonymous
disorder with NMO [19]. Lau et al. reported that up to
36% of MS cases in Hong Kong had selective involvement of
the optic nerves and spinal cord [20], and NMO comprised
17% of possible MS cases in French Afro-Caribbeans in
Martinique[21].Inapopulation-basedstudyinCuba,NMO
comprised approximately 10% of demyelinating disorders
[22]. In contrast, in countries consisting of a predomi-
nately white population, NMO comprised less than 2%
of all demyelinating disorders, and the majority of cases
occurred in white patients [23]. Similarly, in the Mayo series,
Wingerchuk et al. found that NMO still tends to occur
predominately in white populations [3].
Our experience at the NMO clinic at Johns Hopkins
Medical Institution has shown a signiﬁcant racial pre-
dilection for NMO with African American populations
comprising approximately 50% of patients, which is clearly
epidemiologically distinct from MS (unpublished data).Neurology Research International 3
Of note, there is a diﬀerential demographic proﬁle in
monophasic and relapsing NMO, with a stronger female
predominance in relapsing NMO (female:male = 9:1),
whilemonophasicNMOseemstoequallyaﬀectbothgenders
(female:male = 1:1). In addition, the median age of onset
in monophasic NMO is a decade earlier than relapsing NMO
(29 years versus 39 years, resp.) [3].
4.Genetics
The distinct racial predilection of NMO suggests a possible
genetic etiological contribution. Although there have been
a handful of reports on familial cases of NMO, to date, a
convincing human leukocyte antigen (HLA) class II allele
association has not been established [24–27].
5.RadiologicalFeatures
5.1. Conventional Imaging Techniques. Conventional MRI is
an important tool in the diagnosis of NMO. A classic MRI
feature that is seen in the majority of NMO patients is
a longitudinally extensive transverse myelitis (LETM) that
spans more than 3 vertebral levels, which is associated with
cord swelling and gadolinium enhancement in many cases
(Figure 1). The extent of the longitudinally extensive lesion
in the cord, however, can be related to the proximity to the
attack; therefore, in some cases the absence of LETM does
not necessarily exclude the diagnosis of NMO. Cord atrophy
can be observed in 22% of cases with follow-up imaging.
Enhancement along the course of the optic nerve is another
typical ﬁnding if the MRI is performed in close temporal
proximity (within two weeks) of the onset of symptoms of
optic neuritis [3].
Although a “normal” MRI of the brain was initially
thought to be a criterion of NMO, subsequent investigations
conﬁrm that the MRI brain is, in fact, abnormal in the
majority of NMO patients. In patients with clinical and
radiological features otherwise typical for NMO, 60–85% of
cases have been shown to have abnormal brain lesions. Over
time, up to 10% of patients develop lesions typical of MS
[28, 29].
Lesions involving the diencephalon and brainstem dis-
tinctly atypical for MS have been commonly reported
in NMO patients [8, 29, 30]. These distinctive lesions
predominately involve the hypothalamus and can extend
to brain tissue surrounding the third and fourth ventricle
and aqueduct of Sylvius and seem to be characteristic
brain lesions of NMO. In a subsequent study, Pittock et al.
demonstrated that these regions correspond with areas of
AQP4 channel localization, which supports the notion that
this area is particularly sensitive to pathogenic NMO-IgG
[31].
The revised diagnostic criteria for NMO recognize the
common brain abnormalities seen in NMO patients and
were modiﬁed to include patients with abnormal brain MRI
atypical for MS, rather than those with normal brain MRI
[14].
5.2. Advanced Imaging Techniques. Advanced MRI tech-
niques have enabled the establishment of further distinctions
between NMO and MS patients, which increasingly supports
the notion that NMO is a distinct disease entity. Filippi et al.
demonstrated normal magnetization-transfer ratio (MTR)
in the normal-appearing braintissue of NMOpatients, while
patients with MS showed a signiﬁcantly decreased MTR. In
the spinal cord, on the other hand, MTR was signiﬁcantly
diminished in both NMO and MS patients. These ﬁndings
correspond with clinical observations and suggest that the
brain lesions of NMO are less destructive and, therefore
more commonly asymptomatic, while spinal cord lesions
tend to be much more destructive, and, therefore, more
clinically symptomatic [32]. A subsequent study using both
diﬀusion-tensor and magnetization-transfer imaging of the
brain assessed normal-appearing gray and white matter
separately in NMO and demonstrated no abnormalities in
normal-appearing white matter, but diminished MTR and
increased mean diﬀusivity (MD) in the normal-appearing
gray matter, suggesting the presence of tissue disruption in
the gray matter of NMO patients [33].
More recently, Yu et al. demonstrated the presence of
abnormal diﬀusion (lower fractional anisotropy and higher
mean diﬀusivity) in the white matter and gray matter of
NMO patients in comparison to controls. Interestingly,
further analysis of the white matter abnormalities showed
that regions connected to the optic nerves and spinal cord
had abnormal diﬀusion, while regions unconnected to the
optic nerves and spinal cord demonstrated normal diﬀusion.
This ﬁnding suggests that the observed abnormalities in
water diﬀusion of the white matter tracts in NMO are largely
caused by secondary degeneration from primary lesions in
the optic nerves and spinal cord, rather than independent
lesions [34]. A more recent study investigating the normal-
appearing white matter in the spinal cord of NMO patients
conﬁrmed the presence of abnormal diﬀusion (diminished
fractional anisotropy, elevated mean, and perpendicular
diﬀusivity) in normal-appearing white matter and demon-
strated a signiﬁcant correlation of diﬀusion-tensor imaging-
derived indices to global measures of clinical dysfunction.
Based on these ﬁndings, the authors postulated that the
pathological substrate of clinical dysfunction in NMO was
more likely due to demyelination rather than axonal loss and
that diﬀusion-tensor imaging-based indices may be useful as
biomarkers for NMO [35].
5.3. Optical Coherence Tomography. Optical coherence to-
mography is an increasingly utilized method to visualize
retinal pathology in optic-nerve-related disorders. de Seze et
al. demonstrated a signiﬁcantly thinner retinal nerve ﬁber
layer (RNFL) in NMO patients in comparison to controls
and a signiﬁcant correlation to EDSS, a global measure of
disability [36]. Subsequent reports comparing NMO and MS
patients found that the RNFL in NMO patients is thinner
on average, and that, after an episode of optic neuritis, the
RNFL is signiﬁcantly thinner in NMO patients, suggesting
more substantial retinal damage following optic neuritis in










Figure 1: An MRI showing a longitudinally extensive cervical spinal cord lesion in a patient with NMO. (a) T2 weighted sagittal MRI
sequence shows T2-hyperintensity extending beyond 3 spinal cord levels. (b) T2-weighted axial sequence shows bilateral T2 hyperintensity
in the central/dorsal cord. (c) T1-weighted sagittal sequence with gadolinium contrast shows enhancement in a signiﬁcant portion of the
lesion.
Taken together, these ﬁndings conﬁrm the utility of
novel imaging techniques in providing increasing insight
into NMO disease mechanisms.
6.LaboratoryFindings
Cerebrospinal ﬂuid (CSF) analysis in NMO shows non-
speciﬁc abnormalities in the majority of cases. Pleocytosis
is observed in 30–79% of patients with an acute exacer-
bation [3, 10, 13], with approximately 13–35% showing
>50cells/mm3, which is an uncommon ﬁnding in MS [3,
10, 18]. A neutrophilic pleocytosis is found in 17–57% of
patients[3,13],andoligoclonalbandsarepresentin17–43%
of patients [3, 10, 13, 18]. CSF protein is elevated in 25–30%
of patients [10, 18].
Laboratory evidence of non-organ-speciﬁc systemic au-
toimmunity is also common, and up to 25–44% of patients
with or without clinical evidence of a systemic autoimmune
disorder have a positive antinuclear antibody [3, 13, 18, 39].
Other non-organ-speciﬁc autoantibodies (SSA, SSB) are also
commonlyseeninNMOpatients,andsystemicautoimmune
disorders such as Sjogren’s Syndrome (SS) and systemic
lupus erythematous (SLE) can occur concomitantly with
NMO, which likely reﬂects an underlying predisposition for
these patients to develop autoimmune disorders. A study by
Pittock et al. in 2008 demonstrated the utility of NMO-IgG
in distinguishing patients with concurrent NMO spectrum
disorders and a systemic autoimmune disease from those
with a neurological complication of systemic autoimmune
disease. Patients with SS or SLE who were NMO-IgGpositive
were likely to have a history of transverse myelitis or optic
neuritis, which suggests the coexistence of a NMO spectrum
disorder with their systemic autoimmune disorder. On the
other hand, patients seronegative for NMO-IgG did not
develop optic neuritis or transverse myelitis, conﬁrming the
speciﬁcity of this antibody in detecting NMO and suggesting
that the presence of NMO-IgG is not an epiphenomenon of
general systemic autoimmunity [39].Neurology Research International 5
7. Anti-Aquaporin-4Antibody (NMO-IgG)
The discovery of the NMO-IgG has played a pivotal role
in the diagnosis and elucidation of disease mechanisms in
NMO.
The discovery of an NMO disease-speciﬁc antibody
(NMO-IgG) by Lennon et al. in 2004 was fuelled by the
observation that immunoglobulin and complement depo-
sition in active lesions followed a distinct rim and rosette
vasculocentric pattern, suggesting an antibody-mediated
mechanismofdisease[40].Later,thetargetofNMO-IgGwas
identiﬁed to be the aquaporin-4 (AQP4) water channel [41].
The sensitivity and speciﬁcity of the NMO-IgG in identi-
fying NMO in the Lennon et al. series were 73% and 91%,
respectively [40]. Subsequently, multiple groups have vali-
dated the speciﬁcity of the NMO-IgG in identifying NMO
using various immune assays. Waters and Vincent compared
the sensitivities and speciﬁcities of the ﬁve main methods
developedinrelapsingNMOpatients,whichincludeindirect
immunoﬂuorescence(IIF),acell-basedassay(CBA),aradio-
immunoprecipitation assay (RIPA), a ﬂuoroimmunopire-
ciptation assay (FIPA), and enzyme-linked immunosorbent
assay. All techniques had high speciﬁcities, ranging from 91
to 100%, with the CBA and FIPA both having speciﬁcities
of 100%. Sensitivities, on the other hand, varied and ranged
from57to91%,withIIF,FIPA,andCBAshowingthehighest
sensitivities at 86, 83, and 91%, respectively [42].
There is evidence that rates of NMO-IgG seropositivity
in patients meeting clinical diagnostic criteria for NMO may
vary signiﬁcantly depending on the population being tested.
A study comparing NMO-IgG seropositivity in patients
fulﬁlling the 1999 Wingerchuk diagnostic criteria for NMO
in the Caribbean and Europe demonstrated a lower rate in
theCaribbean(33.3%),ascomparedwithCaucasianpatients
from Spain and Italy (62.5%) and France (53.8%) [43].
In comparison, 2 studies of NMO-IgG detection rates in
Japanese patients with OSMS and LETM varied signiﬁcantly,
with one reporting NMO-IgG seropositivity in 60% of
patients, [44] while another reports seropositivity in 35% of
such patients [45].
At present, it is unclear whether there is truly a subset
of patients with clinical NMO that are NMO-IgG negative,
or if this is a result of inadequate sensitivity of existing
immunoassays to detect the antibody, or inadequately sen-
sitive and speciﬁc diagnostic criteria, or a combination of
all of these factors. Given the variability in the diagnostic
properties of diﬀerent assays, until further insight is available
into this issue, current expert recommendations are to test
for the presence of NMO-IgG using two separate detection




AQP4 is an integral homotetrameric protein complex and
is expressed primarily on the abluminal surface of astrocyte
foot process and can also be found on ependymocytes and
endothelial cells [48]. It is one of the main water channels in
the central nervous system but is also found outside of the
central nervous system in many solid organs including renal
distal collecting tubules and in a portion of gastric parietal
cells. In astrocytes, AQP4 is anchored by a dystroglycan
complex [49] and is found in highest concentrations in
astrocytes having direct contact with capillaries and pia
in the brain and spinal cord [50]. AQP4 likely acts in
concert with potassium and bicarbonate channels to regulate
water dynamics in the CNS between brain, blood, and
CSF and is therefore an integral element of brain volume
and ion homeostasis [48, 49]. AQP4 has also been shown
to play a role in astrocyte migration and neural signal
transduction in animal models [51]. The absence of AQP4
in knockout mouse models is known to exacerbate the
recovery from vasogenic edema, and AQP4 has been shown
to mediate cerebral edema in various models of neurological
injury, including epilepsy, ischemia, and trauma [52, 53].
Interestingly, a recent study in AQP4-knockout mice found
that experimental autoimmune encephalomyelitis (EAE)
was attenuated in comparison to wild-type mice, which
implicates AQP4 as a novel disease determinant of the
severity ofEAEandlikely otherautoimmune disorders ofthe
CNS [54].
Zhang and Verkman demonstrated the presence of
high concentrations of AQP4 in perivascular astrocytic
foot processes in the cerebral cortex, subependymal and
vasculocentric regions of the brainstem, and gray and white
matter of the spinal cord, and in a vasculocentric pattern
in the optic nerves [55]. This pattern seems to coincide,
for the most part, with sites of preferential lesion formation
in NMO. However, the presence of high concentrations of
AQP4 in astrocytic foot processes in the cerebral cortex, as
well as in retinal Muller cells [48], which are not areas in
which NMO lesions are typically seen clinically, suggests that
there is selectivity of AQP4 involvement in the pathogenesis
of NMO.
Basic structural pathology of the spinal cord in NMO
typically shows extensive demyelination across multiple
levels associated with necrosis, cavitation, and axonal loss,
involving both the gray and white matter. Lesions typically
localize to the central cord, and there is evidence of myelin
preservation in the periphery, with a signiﬁcant loss of
oligodendrocytes. In chronic lesions, evidence of gliosis,
atrophy, and cavitation is commonly seen. The optic nerves
and chiasm have also been reported to show inactive
demyelination, partial remyelination, as well as gliosis and
cavitation [56, 57].
Nagelhus et al. described two distinct types of NMO
lesions: those with AQP4 loss and demyelination and
necrosis, which are typically seen in the optic nerve and
spinalcord,andthosewithAQP4losswithoutdemyelination
or necrosis, which are typically seen in the medulla and area
postrema [49]. The absence of demyelination and necrosis
in the latter type of lesions corresponds to the reversible
nature of MRI lesions in the medulla and area postrema, as
well as resolution of clinical dysfunction attributable to these
regions [5].
Inﬂammatory inﬁltrates within active demyelinating
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microglia, numerous B lymphocytes, occasional CD3+ and
CD8+ T lymphocytes, as well as prominent perivascular
granulocytes and eosinophils. In early active demyelinating
lesions, there is prominent IgG and complement reactivity
and macrophage staining in a distinct perivascular rosette
pattern, as well as along the rim of thickened vessel walls,
suggestingaroleforhumoralautoimmunityinNMOdisease
mechanisms [56–58].
Accumulating pathological evidence is convincing that
thetargetedattackofAQP4bytheNMO-IgGisanimportant
initiating event in the development of NMO. The discovery
ofadisease-speciﬁcautoantibodyinNMO,theidentiﬁcation
of AQP4 as the antibody target [40, 41], and the demon-
stration that most NMO lesions have marked loss of AQP4
provide support for this hypothesis [49]. Furthermore, in
NMO lesions, the pattern of AQP4 loss has been shown
to correspond to the characteristic vasculocentric rim and
rosette pattern of IgG and complement deposition. Finally,
areaswithmarkedAQP4lossconcurrentlyshowsigniﬁcantly
reducedstainingforglialﬁbrillaryastrocyticprotein(GFAP),
with relatively preserved myelin-basic protein, suggesting
that astrocytes are the primary target of the NMO-IgG
[58]. Taken together, these pathological ﬁndings support
the notion that a targeted attack of AQP4 in astrocytic
foot processes plays a prominent role in NMO pathogenesis
involving an immune cascade of events which ultimately
results in the clinical manifestations of the disease.
Diﬀerent hypotheses on the exact immunopathogenic
mechanisms by which NMO-IgG exerts it eﬀects have
been promoted by separate groups. Lucchinetti et al. have
postulated that binding of NMO-IgG to AQP4 initiates two
separate events: activation of the lytic complement cascade,
and downregulation of AQP4 by endocytosis and degra-
dation [56, 59–61]. A few important observations support
thisnotion,including:thecolocalizationofimmunoglobulin
with a marker of the terminal lytic complement complex
(C9neo antigen), the presence of activated macrophages and
signiﬁcant vascular hyalinization in perivascular regions in
active NMO lesions [56], and in vitro experiments which
demonstrate the colocalization of AQP4 with EAAT2, a
glutamate transporter and the fact that AQP4 and EAAT2
were endocytosed in the presence of NMO-IgG [59]. Based
on these observations, Hu and Lucchinetti propose that
binding of NMO-IgG to AQP4 in astrocytic foot processes
initiates complement-mediated eﬀects but also disrupts
glutamate homeostasis, which can lead to oligodendrocyte
injury in the spinal cord and optic nerves, both of which
are highly sensitive structures to ﬂuctuations in ambient
glutamate concentrations [61]. In addition, they postulate
that aberrations in glutamate homeostasis render these
structures more sensitive to complement-mediated attacks.
On a similar note, Misu et al. found signiﬁcantly diminished
AQP4 and GFAP staining, most prominently in perivascular
regions with complement and immunoglobulin deposition
with relative preservation of myelin-basic protein. The
conclusion from this group was that these observations
provide further support for the hypothesis that astrocytic
impairmentassociatedwithhumoralautoimmunitydirected
against AQP4, which causes AQP4 downregulation, is the
primary immunopathogenic mechanism in NMO [58].
By way of comparison, Parratt and Prineas demonstrated
in pathological case series examining NMO versus MS
lesions that the chief pathological feature unique to NMO
was not downregulation of AQP4 expression, but an early
complete destruction of perivascular astrocytes, with gliosis
initiated by a population of astrocyte progenitors [62].
Although this conclusion can still support an important
pathogenic role of NMO-IgG and complement-mediated
damage to astrocytes in NMO, it raises the possibility that
the acute breakdown of large numbers of astrocytes may in
fact be the initiating factor for the generation of NMO-IgG,
rather than vice versa.
More recently, in a pathological case series of NMO ver-
sus MS lesions, Matsuoka et al. found signiﬁcant variability
in the degree of AQP4 loss in actively demyelinating lesions
in between patients with NMO and signiﬁcant lesion-to-
lesion heterogeneity of AQP4 expression even in patients
with preferential AQP4 loss. The authors also observed
signiﬁcant variability in the relationship between AQP4 loss
andtheperivasculardepositionofactivatedcomplementand
immunoglobulin. Furthermore, diﬀerent patterns of AQP4
loss and perivascular deposition of activated complement
and immunoglobulins were observed even within a single
lesion. The conclusion from this study was that that there
is a heterogeneous relationship between anti-AQP4 antibody
and loss of AQP4 expression and that AQP4-mediated
immunological destruction may not be the sole mechanism
by which NMO lesions are formed [63].
Animal studies have shed some insight into the complex-
ity of NMO disease mechanisms by demonstrating that the
presence of the NMO-IgG alone is not directly pathogenic.
Kinoshita et al. demonstrated that while passive transfer of
IgG obtained from NMO patients to EAE-induced Lewis
rats resulted in active lesions with histopathological features
suggestive of those observed in human NMO [64], a
subsequent study by Bradl et al. showed that the infusion of
IgG from NMO patients to healthy (i.e., non-EAE) rats does
not cause lesions or clinical symptoms suggestive of human
NMO [65]. These ﬁndings suggest that human NMO-IgG in
and of itself is not pathogenic in rodents but requires the
presence of T-cell-mediated CNS inﬂammation to exert its
pathogenic eﬀects. Clinical reports of NMO-IgG identiﬁed
in patients many years before the clinical onset of symptoms
[66, 67] and a signiﬁcant portion of patients reporting
antecedent viral infections prior to symptom onset are both
supportiveofthishypothesis[3].Itisworthnoting,however,
that the pathogenic eﬀects of human NMO-IgG infused
into these EAE mice may have been exaggerated due to the
species-speciﬁc nature of complement inhibitors, which are
typically abundant throughout the CNS.
In addition to T-cell-mediated CNS inﬂammation, a
complex array of immune cells are evidently at play in NMO
disease pathogenesis. Recently, Chihara et al. demonstrated
that a subpopulation of B cells resembling plasmablasts
was increased in the peripheral blood of patients with
NMO and that this population of cells was predominately
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IL-6 was found to increase the survival of this population
of plasmablasts and blockade of IL-6 receptor signaling
reduced their survival. From a therapeutic perspective, this
is of signiﬁcant interest in NMO as IL-6 receptor blockading
agents (tocilizumab) are already approved for clinical use
in the treatment of other autoimmune disorders such as
rheumatoid arthritis [68].
To date, an animal model that recapitulates all aspects
of human NMO has yet to be identiﬁed. The development
of such a model of disease will enable further elucidation of
proposed disease mechanisms. Until then, we will continue
to use various animal models including those that are based
on EAE with passive transfer of NMO-IgG.
Taking all of the aforementioned pathological, in vitro,
and animal studies into account, it is evident that NMO-
IgG plays an important role in NMO disease mechanisms,
However, at present, it is diﬃcult to derive any deﬁnitive
conclusions on the speciﬁc role of AQP4 in evolving NMO
lesions. The development of more accurate animal models of
NMO and further pathological studies in humans will allow
clariﬁcation of the precise sequence of pathological events in
NMO.
9. Treatment
9.1. Treatment of Acute Relapses. Acute relapses of NMO are
generally treated with high-dose intravenous methylpred-
nisolone at 1g daily for 3–5 days. In some cases, this is
followed by an oral prednisone taper. This practice is based
onevidencefromMStreatmenttrialsratherthananyspeciﬁc
controlled trials in NMO patients. Observational studies
haveshownthatthemajorityofpatients(80%)improvewith
a short course of methylprednisolone [3].
The eﬃcacy of PLEX has been evaluated in a series of
retrospective studies which demonstrated clinical improve-
ment in 50–60% of steroid-refractory NMO patients who
were treated with PLEX [69, 70], as well as signiﬁcant clinical
improvement in PLEX-treated patients in comparison to
those treated with steroids alone [71]. A randomized, sham-
controlled trial demonstrated the eﬃcacy of PLEX in a
combination of acute CNS demyelinating diseases, which
included 2 cases of NMO. The proportion of patients with
clinical improvement was signiﬁcantly higher in patients
who had undergone PLEX in comparison to sham treatment
(42.1% versus 5.9%) [72]. The typical courses of PLEX used
in these reports consisted of 4–7 exchanges over a period of
5–14 days.
The literature supporting the use of IVIG in NMO
relapses is sparse and includes only one isolated case report
[73]. Therefore, there is insuﬃcient evidence to support the
utility of IVIG in the treatment of acute relapses of NMO.
9.2. Preventive Treatment. The preventive treatments used in
NMO are based largely on retrospective or open-label trials
and case series, which makes it diﬃcult to draw deﬁnitive
conclusions on the eﬃcacy of many of these agents. A
summary of the existing evidence for various preventive
agents is presented below.
9.2.1. Immunomodulatory Agents. The use of IFN-beta-1b
in the preventive treatment of NMO has been reported
predominately in the context of Japanese OSMS, and most
reports support the notion that interferons are not helpful
and may even be harmful in these patients. Uzawa et al.
compared the eﬃcacy of IFN-beta-1b in NMO versus MS
patients and found that this agent was ineﬀective in NMO
patients [74]. Warabi et al. reported clinical relapses con-
sisting of optic neuritis and myelitis in patients with OSMS
treated with IFN-beta-1b [75]. Shimizu et al. reported the
development of tumefactive brain lesions in 2 NMO patients
treatedwithIFN-beta-1b,withcompleteclinicalstabilization
after the initiation of immunosuppressive treatment with
azathioprine [76]. More recently, in a retrospective analysis
of carefully selected patients with “genuine” OSMS (rather
than NMO), Shimizu et al. reported a signiﬁcant therapeutic
beneﬁt of IFN-beta-1b, with diminished relapse rates and
disability progression [77]. In a retrospective analysis con-
ductedbyPapeixetal.comparingNMOpatientstreatedwith
various immunosuppressive agents versus interferon-beta
treatment, those treated with immunosuppressive agents
showed a signiﬁcant decrease in relapse rate [78]. A recent
case report by Palace et al. reported clinical relapses and high
anti-AQP4 Ab titres in a patient with NMO treated with
interferon-beta-1a and subsequent clinical stabilization and
lower titres with the initiation of azathioprine [79]. Taken
together, the existing literature does not support the use of
interferon-beta immunomodulatory treatment in NMO and
even suggests that these agents may exacerbate the disorder.
An important caveat to this conclusion, however, is that,
in some cases of “genuine” OSMS, IFN-beta-1b may have
therapeutic eﬃcacy.
On the other hand, the use of Copaxone, another
ﬁrst-line immunomodulatory agent used in MS, has been
reported in the context of NMO in only two case reports,
both which showed a beneﬁcial response [80, 81].
9.2.2. Immunosuppressive Agents. The humoral-mediated
immune mechanisms underlying NMO provide theoretical
support for the use of rituximab, which is a monoclonal
antibody targeting CD20, a protein present on the sur-
face of mature B-lymphocytes. The role of rituximab in
ameliorating NMO disease mechanisms by B-lymphocyte
depletionhasyettobedeﬁnitelyclariﬁed,butrecentevidence
demonstrating that CD20-negative plasmablasts are the
main subgroup of B-cells responsible for the production
of NMO-IgG [68] suggests that rituximab acts through
mechanisms other than diminishing the production of
antibodies, and possibly via antigen-presenting cells [82].
TheeﬃcacyofrituximabinNMOwasinitiallydemonstrated
in an open-label trial by Cree et al. where 8 NMO patients
were treated and followed for a mean of 12 months. The
majority (75%) of patients remained relapse-free at follow-
up, and all but one patient (87.5%) showed signiﬁcant
neurological improvement. Rituximab was well tolerated in
this trial, and no patients experienced any serious adverse
reactions [82]. A subsequent retrospective multicenter case
series of 25 patients by Jacob et al. showed a signiﬁcant
decrease in relapse rate at a median follow-up of 19 months,8 Neurology Research International
as well as disability stabilization or improvement in the
majority of patients (80%). Of note, 20% of patients in this
series developed new or reactivated infections, and 1 patient
died of sepsis [83]. In support of the safety proﬁle of this
agent, the literature on the use of rituximab in hematological
and rheumatological disorders conﬁrms the long-term safety
of this agent, with serious adverse eﬀects seen in only a small
minority of patients [84] .Ar e c e n tr e p o r tb yt h eE u r o p e a n
FederationofNeurologicalSocietiesbyZhangandVerkaman
recommends rituximab as a ﬁrst-line agent [55], which has
also been our practice at Johns Hopkins.
The optimal dosing regimen of rituximab has yet to be
determined, and existing studies have utilized diﬀering dos-
ing regimens. Our practice at Johns Hopkins has been to give
a single dose of rituximab at 1000mg intravenously initially,
followed by a repeat dose of 1000mg intravenously after two
weeks. Thereafter, CD19/20 cell counts are monitored on a
monthly basis. When the CD19/20 cell counts climb above
0.1% of the total lymphocyte count, patients are given the
same double dose of rituximab (1000mgiv × 1, followed
by 1000mgiv after two weeks). If the CD19/20 cell count is
undetectable 6 months after the last dose, a single dose of
1000mgivisgiven,andCD19/20countsarefollowedclosely.
In children, an initial single dose of rituximab of 375mg/m2
is given, and this dose is repeated when the CD19/20 cell
count climbs above 0.1% as in adults. Further laboratory
parameters to routinely monitor are outlined in Table 1.
Azathioprine (AZA) is an oral immunosuppressive agent
commonly used in organ-transplant-related immunosup-
pression, as well as in the treatment of systemic autoimmune
disorders such as SLE and rheumatoid arthritis. AZA is a
purine antagonist that interferes with DNA and RNA syn-
thesis, which results in immune cell inhibition by a variety of
mechanisms.TheeﬃcacyofAZAinthepreventivetreatment
of NMO patients was described by Mandler et al. in an open-
label prospective trial of 7 NMO patients, where sustained
disability improvement and the absence of any subsequent
relapses over 19 months was documented in all subjects
[85]. Subsequently, Bichuetti et al. performed a retrospective
review of 36 cases of NMO, of which 27 patients were on
AZA at a mean follow-up of 47 months. AZA alone or
in combination with prednisone was shown to signiﬁcantly
diminish relapse rate and stabilize disability [86]. Of note,
in both reports, there were no serious adverse eﬀects in
any patients treated with AZA. Most recently, Costanzi et
al. performed a retrospective review of 99 patients with
NMO spectrum disorders treated with AZA. AZA used alone
or in combination with prednisone signiﬁcantly reduced
annualized relapse rates by 76%, and in 70 patients with
more than 12 months of follow-up EDSS was stable or
improved in 60% of patients. Of note, 3 cases of lymphoma
were reported in this study [87]. The causal link between
AZA and lymphoma is at present controversial; however,
until further information is available, this is another serious
adverse eﬀect of which clinicians should be aware. The utility
ofAZAindiminishingrelapseratehasalsobeendocumented
in a handful of case reports and case series [76, 78], as well as
a subset of a cohort of NMO patients described by Jarius et
al. [88].
The dosing regimen for AZA varies across diﬀerent
centers, but at Johns Hopkins, our preference is to start
at 2mg/kg/day, divided into two daily doses. If there is no
clinical response, the dose is increased to 3mg/kg/day. For
resistant cases, prednisone at 1mg/kg/day is added or the
decision is made to switch to another immunosuppressive
agent. Patients considering initiating AZA should be tested
for the thiopurine S-methyltransferase (TPMT) mutation,
which is seen in up to 10% of the US population [89].
Individuals harboring this mutation can develop signiﬁcant
bonemarrowtoxicitywithAZA;therefore,thismedicationis
best avoided in these patients. Further laboratory parameters
to monitor are outlined in Table 1.
Mycophenolate mofetil (MMF) is another oral immu-
nosuppressive agent commonly used in organ-transplant-
related immunosuppression and rheumatological disorders.
MMF acts as an inhibitor of a rate-limiting enzyme
in the synthesis of guanine ribonucleotide and 2-deox-
yribonucleotide, which ultimately suppresses the immune
system by inhibiting dendritic cell and T and B lym-
phocyte functioning. The eﬃcacy of MMF in NMO was
described in a retrospective case series of 24 patients with
NMO and NMO spectrum disorders, which demonstrated
a signiﬁcantly diminished relapse rate, as well as stable
or improved disability measures in the majority (91%) of
patients which included rituximab failures. Of note, 25% of
patients reported adverse eﬀects, and 1 patient had a low
WBC count that necessitated discontinuing the medication
[90] .O n es e r i o u sa d v e r s ee ﬀect derived from the transplant
literature is a 14.4 in 100,000 risk of PML [91].
At Johns Hopkins, our practice has been to utilize MMF
as a ﬁrst-line agent. Patients are started on a dose of 500mg
twice daily, which is titrated up to 1000mg twice daily over 4
weeks. At the 4-week mark, the WBC count and diﬀerential
is assessed. The target total WBC count is 3-4 × 103/µL
(approximately half of normal). Alternatively, the target
absolute lymphocyte count is 1-1.2 × 103/µL. The absolute
lymphocyte count should not fall below 1 × 103/µL. If either
target is not attained, the MMF dose is increased by 250mg
twice daily every two weeks, up to a maximum of 1500mg
twice daily. If the target is not attained at the maximum
1500mg twice daily, other immunosuppressive agents such
as rituximab can be considered. While the MMF dose is
being titrated up to the target dose, prednisone is typically
co-administered at 20–30mg daily and weaned oﬀ when the
target MMF dose is reached. Monthly liver function tests
should be performed to rule out toxicity for six consecutive
months while the dose is titrated, then twice yearly thereafter
on a stable dose. Further laboratory parameters to monitor
are outlined in Table 1.
Cyclophosphamide (CYC) is an intravenous immuno-
suppressive drug that acts as a DNA alkylating agent, which
ultimately impairs T and B lymphocyte activity, as well as
variousinﬂammatorycytokines.CYCisusedincombination
withotheragentsinthetreatmentofvariousmalignancies,as
well as in the treatment of systemic autoimmune disorders.
There are no extensive case series or controlled trials on the
use of CYC in NMO, but isolated case reports have shown
a beneﬁcial clinical eﬀect on relapse rate and disability inNeurology Research International 9
Table 1: Recommended ﬁrst-line agents in the preventive treatment of NMO.
Medication Initial dosing Regimen Maintenance dosing regimen Monitoring guidelines
Azathioprine (AZA)
2mg/kg/dayp.o.,
divided into 2 daily
doses
(i) Increase to 3mg/kg/day p.o. if
unsatisfactory response
(ii) Add prednisone 20–30mg p.o. daily if
unsatisfactory response
(iii) Switch to alternate immunosuppressive
agent if unsatisfactory response
(i) TPMT genotyping: avoid use in
TPMT positive patients
(ii) CBC and diﬀerential baseline and
qweekly × 4, qbiweekly × 2, then q1-2
months, LFTs q3months
Mycophenolate mofetil
(MMF) 500mg p.o. bid
(i) Titrate up to 1000mg p.o, bid over 4
weeks
(ii) Check WBC count and diﬀerential at 4
weeks: target total WBC = 3-4 × 103/µLo r
absolute lymphocyte count =1–1.2 × 103/µL
(iii) If target WBC or lymphocyte count
unattained, increase dose by 250mg p.o. bid
every 2 weeks to maximum dose of 1500mg
p.o. bid
(iv) Administer prednisone at 20–30mg p.o.
daily while titrating up MMF, wean oﬀ
prednisone over 6–8 weeks once target dose
attained
(v) Switch to alternate immunosuppressive
agent if target WBC/lymphocyte count not
attained or unsatisfactory clinical response
(i) CBC and diﬀerential at baseline and
qweekly × 4, then qmonthly × 6m o n t h s ,
then q6monthly
(ii) LFTs at baseline and qmonthly × 6
months, then q6monthly
(iii) If clinical suspicious for infection:
septic work-up, including CSF JC virus if
suspicious for PML
Rituximab 1000mgiv × 1d o s e
(i) Repeat 1000mgiv × 1d o s e2w e e k sa f t e r
initial dose
(ii) Check CD19/20 cell counts monthly
(iii) Redose with same double dose
(1000mgiv × 1, followed by repeat dose 2
weeks later) when CD19/20 cell counts >
0.1% total lymphocyte count
(iv) If CD19/20 counts are undetectable 6
months after last dose, redose with single
1000mgiv dose
(i) Baseline and monthly CBC and
diﬀerential, CD19/20 cell count
(ii) Baseline and periodic renal function
tests
(iii) Screen for hepatitis B in high-risk
patients prior to initiation
patients with isolated NMO [73, 88], as well as in patients
with NMO/SLE overlap [92, 93].
Methotrexate (MTX) is a dihydrofolate reductase in-
hibitor and acts by impairing DNA synthesis. MTX is a
commonly used drug in the treatment of systemic autoim-
mune disorders and in combination with other drugs as
a chemotherapeutic agent. The utility of a combination of
MTX and prednisolone in NMO was described in a case
report by Palace et al., where a patient remained relapse-free
3 years after the initiating treatment [79].
Mitoxantrone (MITO) is a synthetic anthracenedione
derivative that acts by inhibiting both DNA and RNA
synthesis, which results in suppression of both T and B
lymphocytes, and inhibition of proinﬂammatory cytokine
secretion. The eﬃcacy of MITO in NMO was demonstrated
in a prospective open-label two-year study where 4 out
of 5 patients (80%) showed signiﬁcant clinical and radio-
graphic improvement. In this study, MITO was generally
well tolerated, with one patient having evidence of sub-
clinical cardiac insuﬃciency that recovered after medication
discontinuation [94]. A subsequent retrospective case series
by Kim et al. showed that MITO resulted in a signiﬁcant
decrease in relapse rate and stabilization or improvement in
measures of disability in all patients. There were no serious
adverse eﬀects in any patients [95]. Despite the apparent
tolerability of MITO in these two trials, experience in MS
and other disorders has shown that MITO can causes serious
toxicity with reports of potentially lethal adverse eﬀects such
as opportunistic infection, cardiac systolic dysfunction, and
therapy-related acute leukemia [96]. Therefore, the clinical
beneﬁts associated with the use of MITO in NMO must be
carefully weighed against the potential serious risks and the
fact that the long-term tolerability in NMO patients remains
unknown.
Case reports have suggested that intermittent IVIG in-
fusions may be of utility in preventing relapses and clinical
deterioration. Bakker and Metz reported 2 cases of NMO
treated with monthly infusions of IVIG that resulted in a
signiﬁcant decrease in relapse rate and clinical improve-
ment [97]. More recently, Okada et al. report a case of
NMO that responded with monthly IVIG with respect
to relapse rate and clinical disability [98] .Ar e c e n tc a s e
series of 2 patients with treatment-refractory NMO showed
a signiﬁcant decrease in relapse rate with the initiation
of intermittent plasmapheresis [99]. Although the existing
evidence is not suﬃcient to recommend intermittent IVIG
as preventive treatment in NMO, it may be considered for
research trials in treatment-refractory individuals.10 Neurology Research International
10. Conclusion
In the past decade, the discovery of a disease-speciﬁc an-
tibody has enabled the establishment of NMO as a distinct
disease entity in the spectrum of CNS demyelinating disor-
ders. What was once thought of as a variant of MS is now
regardedasauniquediseaseentitywithsigniﬁcantlydiﬀerent
prognostic and treatment implications.
Although much progress has been made in clarifying
the clinical, epidemiological, radiographic, and pathological
features of NMO, much remains to be understood. Future
directions of investigation include the development of an
accurate animal model of disease, reﬁnement of immunoas-
says for detection of the NMO-IgG, application of novel
imaging techniques, and clariﬁcation of the epidemiological
and genetic risk factors of NMO. Together, this will enable
earlier disease detection and, ultimately, the development
of more targeted treatment strategies for this debilitating
neurological disorder.
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